Faruqi & Faruqi, LLP Announces the Investigation of VBI Vaccines Inc. (VBIV) Over the Proposed Sale of the Company to SciVac Therapeutics Inc.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of VBI Vaccines Inc. (“VBI” or the “Company”) (NasdaqCM:VBIV) for potential breaches of fiduciary duties in connection with the sale of the Company to SciVac Therapeutics Inc. for approximately $77 million.
The Company’s stockholders will only receive 20.808356 common shares of SciVac for each share of VBI common stock they own, or approximately $2.69 per share. However, at least one analyst sets a VBI target price of $7.00 per share.
If you own common stock in VBI and wish to obtain information and protect your investments free of charge, please fill out the form below or contact Juan Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Juan E. Monteverde
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.